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Avoiding Burnout and Demoralization
Prevalence (%) of Lifetime 
Substance Use Disorder for 
Various Psychiatric Disorders
• Any Substance Use Disorder
• Any Alcohol Use Disorder
• Any Drug Use Disorder
*Data From ECA Study
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Rates of Lifetime Substance Use Disorder (SUD) among 





















Factors Influencing Prevalence 







• Single or never married
• Good premorbid 
functioning
• History of childhood 
conduct disorder
• Antisocial personality 
disorder
• Higher affective 
symptoms
• Family history SUD
Clinical Epidemiology
1. Rates higher for people in treatment
2. Approximately 50% lifetime, 25% 
35% current substance abuse
3. Rates are higher in acute care, shelter,
institutional, and emergency
settings
4. In most settings, alcohol is most commonly 
abused substance
Common Consequences of 
Substance Abuse in 
Schizophrenia




• Housing instability and 
homelessness











Rates of comorbidity for any two disorders tend 
to be higher in clinical samples (vs. general 
population samples) and in treatment settings 
(than non-treatment settings) because either 






















Secondary Substance Abuse Model
Secondary Psychopathology Model
Bi-Directional Model
Secondary Mental Illness 
Models: Schizophrenia
• Chronic stimulant use as precipitant of schizophrenia: 
lack of replication of early findings
• Hallucinogen abuse as precipitant of long-term 
psychosis: clients tend to have relatives with 
psychosis
• Cannabis prospectively predicts onset of 
schizophrenia: 1) can’t explain stable rate of 
schizophrenia following rise in cannabis use; 2) may 







• Secondary psychosocial effects
Self-Medication Hypothesis
• Substance type unrelated  to specific 
symptoms of schizophrenia
• Symptom severity unrelated to substance 
abuse
• Clients usually don’t report substances 
reduce symptoms
General Dysphoria Hypothesis
• Dysphoria common in schizophrenia, usually 
precedes onset of psychosis and persists throughout 
illness
• Some evidence linking trait dysphoria to substance 
abuse in schizophrenia
• Inconsistent findings suggesting link between 
depression and substance abuse in schizophrenia
Super-sensitivity Model
 Biological sensitivity increases vulnerability to effects of 
substances in schizophrenia
 Smaller amounts of substances result in problems
 “Normal” substance use is problematic for clients with 
schizophrenia but not in general population
 Sensitivity to alcohol and other substances, rather than 
high amounts of use, makes many clients with 









Status of Moderate Drinkers with 















Source: Drake & Wallach (1993)
Support for Super-sensitivity 
Model
 People with schizophrenia less likely to develop physical 
dependence on substances
 Standard measures of substance abuse are less sensitive in 
clients with schizophrenia
 Clients are more sensitive to effects of small amounts of 
substances 
 Few clients are able to sustain “moderate” use without 
impairment
 Super-sensitivity accounts for some increased comorbidity
Secondary Psychosocial 
Effects Model
• Psychosocial consequences of schizophrenia 





– Increased sensitivity to stress
– Free time/no work, parenting responsibilities
Common Factor Models
• Genetic vulnerability (not supported)
• Cognitive impairment (limited data)
• Social disadvantages (limited data)
• ASPD
• Conduct Disorder (CD) and ASPD have high comorbidity with 
substance abuse
• CD often precedes onset of schizophrenia
• ASPD has high comorbidity with schizophrenia
• CD and ASPD have a high comorbidity with SUD in clients with 
schizophrenia
• Among dually diagnosed patients, CD and ASPD are associated 
with more severe SUD
Antisocial Personality Disorder (ASPD)
Research
Conclusion
• ASPD is a common factor that may account for some increased 










































Source: Mueser, et. al. (1999)
Summary of Models of 
Comorbidity
• Secondary mental illness: limited support, but drug 
abuse may precipitate earlier age onset of 
schizophrenia in some vulnerable cases
• Secondary substance abuse: support for 
supersensitivity model; marginal support for 
dysphoria hypothesis
• Common factors: support for ASPD
Treatment Barriers
• Historical division of service and training
• Sequential and parallel treatments
• Organizational and categorical funding 
barriers in the public sector
• Eligibility limits, benefit limits, and payment 
limits in the private sector
Integrated Treatment
• Mental health and substance abuse 
treatment
Delivered concurrently
By the same team or group of 
clinicians
Within the same program
The burden of integration is on the 
clinicians





• Reduction of negative consequences
• Stage-wise treatment: engagement, 
persuasion, active treatment, and relapse 
prevention
What are the Stages of 
Treatment?
1. Engagement, persuasion,
active treatment, and relapse
prevention
2. Not linear
3. Stage determines goals
4. Goals determine interventions 
5. Multiple options at each stage
What Do We Do During 
Engagement?






4. Social network support
5. Legal constraints
What Do We Do During 
Persuasion?
• Goal: To motivate the client to address 









What Do We Do During 
Active Treatment?
• Goal:
To reduce client’s use/abuse of substance
• Clinical Strategies
1. Self-monitoring
2. Social skills training












What Do We Do During 
Relapse Prevention?
• Goals:
 To maintain awareness of vulnerability and 
expand recovery to other areas
• Clinical Strategies
1. Self-help groups
2. Cognitive-behavioral and supportive interventions 
to enhance functioning in:




• Construction a relapse prevention plan:
– Risky situations
– Early warning signs
– Immediate response
– Social supports
– Abstinence violation effect
Research on Integrated 
Treatment (IT)
• 26+ RCT or quasi-experimental studies of IT 
(reviewed by Drake et al., 2004)
• 3/4 studies of brief motivational interviewing 
interventions showed positive effects
• 6/7 studies found group intervention better than 12-
step or standard care
Research on IT (Cont.)
• Family intervention: no RCTs examining 
family treatment alone
• Comprehensive IT: 2 RCT & 1 quasi-
exp. study favor comp. IT over 
treatment as usual
• Intensity: more intensive IT produces 
slightly better outcomes (e.g., Drake et 
al., 1998)
Drake et al. (1998)
• 203 clients (77% schizophrenia)
• ACT vs. standard case management (SCM) (both IT)
• 3 year follow-up
• ACT better than SCM in alcohol severity & stage of 
treatment
• No differences in hospitalization, symptoms, quality 
of life
NH Dual Diagnosis Study





Beginning 6 months 12 months 18 months 24 months 30 months 36 months
All DD Patients (N = 203) Patients in Recovery (N = 54)
1. Proportion of days in stable community housing (regular apartment or house, not in hospital, jail, 
homeless setting or doubling with friends or family) increased for all dual diagnosis clients.
2. They increased more rapidly for persons in recovery (no substance abuse for at least 6 months).
NH Dual Diagnosis Study
1. Percentage of persons hospitalized during each six months declined 
significantly for all clients.
2. It declined much more for those in recovery.









Beginning 6 months 12 months 18 months 24 months 30 months 36 months
All DD Patients (N = 203) Patients in Recovery (N = 54)
Fidelity to IT Model 
Improves Outcome
Limitations of Research
• Lack of standardization of treatments
• No or limited fidelity assessment
• No replication of program effects
• Unclear or variable comparison conditions
Conclusions
• Substance use disorders are common in schizophrenia and 
contribute to worse outcomes
• Increased comorbidity is due partly to high sensitivity to effects 
of substances, and ASPD operating as a common factor 
increasing risk of each disorder
• Integrated treatment models treat both disorders concurrently, & 
employ motivation-based, comprehensive interventions
• Early research on integrated treatment provides evidence 
supporting its effects on improve substance abuse
